Clinical Trial Update: Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial updates trametinib combined with an AKT inhibitor (GSK2141795) in metastatic triple-negative breast cancer; study completed with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Carcinoma
• Invasive Breast Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• GSK2141795 (GSK2141795)
• Trametinib (trametinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Status: COMPLETED | Results posted: 2019-09-20